Target Identification on non-coding RNA
CLOVERNA is a biotech company expanding non-coding RNA targeted drug discovery with original CRISPR/dCas13-based target identification technology. CLOVERNA’s platform allows us to identify novel disease-associated specific RNA interaction. Long non-coding RNA (lncRNA) is emerging drug discovery target, however there is technical challenge to identify drug discovery target on lncRNA. Our technology allows us to discover selective RNA-interaction modifier (SRiM), which is new concept of oligonucleotide drug targeting lncRNA.
Innovative lncRNA targeted Drug Discovery
Many lncRNAs have multiple interactions with DNA, RNA and protein on single lncRNA. Our approach is to identify sequence for disease specific interaction on lncRNA and discover SRiM to treat intractable diseases with high unmet medical need.
<Publications>
Yurika Shimizu, et al., An RNA-immunoprecipitation via CRISPR/dCas13 reveals an interaction between the SARS-CoV-2 5’UTR RNA and the process of human lipid metabolism. Sci Rep. 2023 Jun 27;13(1):10413. doi: 10.1038/s41598-023-36680-6.